NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,677.4 mln
Float49.74 mln
Earnings Date07/30/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-0.54
Highly suspicious
1-Year Forecast
41.12
Exceptional upside
Relative Strength
76
/ 100
Strongly outperforming
Debt / Equity
0.01
Debt-free
ROE
-27.28
Deeply negative
Business Description
Agios Pharmaceuticals is a US-based drug development company focused on treating blood disorders by targeting how cells produce and use energy. Its main product, PYRUKYND, is approved for adults with pyruvate kinase deficiency and is being tested for sickle cell disease and use in children, while a related treatment called AQVESME addresses a range of thalassemia conditions. The company also has several other therapies in development targeting rare blood and genetic disorders. Founded in 2007 and based in Cambridge, Massachusetts, Agios continues to build a pipeline aimed at diseases with limited existing treatment options.
